Cargando…

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

BACKGROUND: Glioblastoma (GBM) is the most malignant primary tumor in the brain, with poor prognosis and limited effective therapies. Although Bevacizumab (BEV) has shown promise in extending progression-free survival (PFS) treating GBM, there is no evidence for its ability to prolong overall surviv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Minjie, Zhou, Zhirui, Huang, Xiao, Chen, Zhenchao, Zhang, Licheng, Zhang, Jinsen, Hua, Wei, Mao, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265794/ https://www.ncbi.nlm.nih.gov/pubmed/37316802 http://dx.doi.org/10.1186/s12885-023-11043-6

Ejemplares similares

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Gene clusters based on OLIG2 and CD276 could distinguish molecular profiling in glioblastoma
por: Fu, Minjie, et al.
Publicado: (2021)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and Irinotecan
por: Aquino, Domenico, et al.
Publicado: (2014)

Distinct aneuploid evolution of astrocytoma and glioblastoma during recurrence
por: Zhang, Jinsen, et al.
Publicado: (2023)

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
por: Nagpal, Seema, et al.
Publicado: (2011)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
por: You, Weir-Chiang, et al.
Publicado: (2023)

LMAP-05 BEVACIZUMAB AND GAMMA KNIFE RADIOSURGERY IN THE TREATMENT OF FIRST-RECURRENCE GLIOBLASTOMA
por: Zhang, Jeff, et al.
Publicado: (2023)

Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
por: Liu, Zhiguang, et al.
Publicado: (2015)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Omar, Ayman I.
Publicado: (2014)

“Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab
por: Yamamoto, Yohei, et al.
Publicado: (2017)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2018)

Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
por: Vaios, Eugene J, et al.
Publicado: (2020)

Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials
por: Chen, Zhouqing, et al.
Publicado: (2018)

DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker
por: Zhang, Jingwen, et al.
Publicado: (2021)

Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
por: Almubarak, Mohammed, et al.
Publicado: (2008)

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
por: Chen, Clara, et al.
Publicado: (2015)

An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas
por: Laffaire, Julien, et al.
Publicado: (2014)

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma
por: Urup, Thomas, et al.
Publicado: (2020)

Value of [(18)F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab
por: Graham, Maya S, et al.
Publicado: (2020)

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
por: Ansstas, George, et al.
Publicado: (2016)

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts
por: Bota, Daniela A, et al.
Publicado: (2018)

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
por: Arakawa, Yoshiki, et al.
Publicado: (2013)

Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report
por: OKITA, YOSHIKO, et al.
Publicado: (2015)

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019)

ACT-03 Clinical outcome and radiological findings of patients with recurrent glioblastomas treated by bevacizumab
por: Handa, Hajime, et al.
Publicado: (2020)

Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients
por: Gerstner, Elizabeth R, et al.
Publicado: (2020)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
por: Nishikawa, Masahiro, et al.
Publicado: (2021)

Treatment response of bevacizumab combination chemotherapy in recurrent glioblastoma: A long-term retrospective study in Taiwan
por: Huang, Yu-Kai, et al.
Publicado: (2020)

Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases
por: Yang, Gang, et al.
Publicado: (2022)

Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma
por: Mao, Xing-gang, et al.
Publicado: (2016)

Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence
por: Christ, Sebastian M., et al.
Publicado: (2023)

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
por: Cloughesy, Timothy F, et al.
Publicado: (2020)

Role of bevacizumab therapy in the management of glioblastoma
por: Peak, Scott J, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_t1ef237v65ufecmarc2ng05v4n